Serine Protease 3 Promotes Progression of Diffuse Large B-Cell Lymphoma and Serves as a Novel Prognostic Predictor

Table 1

Correlations between PRSS3 expression and DLBCL patients’ features.

Variables	Cases	PRSS3 protein level		value
	()	Low ()	High ()
Sex				0.763
Female	63	31	32
Male	92	43	49
Age				0.784
≤60.0 yrs	82	40	42
>60.0 yrs	73	34	39
B symptoms				0.125
Absence	95	50	45
Presence	60	24	36
Ann Arbor stage				0.008
I-II	79	46	33
III-IV	76	28	48
ECOG PS				0.002
0-1	114	63	51
≥2	41	11	30
Serum LDH level				0.003
Normal	73	44	29
Elevated	82	30	52
ENI				0.659
<2	102	50	52
≥2	53	24	29
Bulky tumor				0.785
No	120	58	62
Yes	35	16	19
IPI				<0.001
0-2	106	64	42
3-5	49	10	39
COO (Hans)				0.722
GCB	71	35	36
ABC	84	39	45

Abbreviations: PRSS3: serine protease 3; DLBCL: diffuse large B-cell lymphoma; ECOG PS: Eastern Cooperative Oncology Group performance status; LDH: lactate dehydrogenase; ENI: extra nodal involvement; IPI: International Prognostic Index; COO: cell-of-origin; GCB: germinal center B cell; ABC: activated B cell.